David Solomon
Chief Executive Officer Thalia Therapeutics
Seminars
Thursday 28th January 2027
Leveraging Bispecific RNAi Approaches to Reduce Global Cardiovascular Risk
11:00 am
- Defining cardiovascular risk among a population with Atherosclerotic Cardiovascular Disease
- Using bispecific strategies to target appropriate cardiovascular receptors and markers
- Developing new RNAi medicines to reduce global cardiovascular risk
